Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced it closed the acquisition of substantially all assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai for a total purchase price of $8 million payable in cash and Shuttle common stock, plus a contingent $2 million in cash and stock tied to performance milestones.
An initial $3 million was paid at closing; remaining consideration will be delivered over time and, for contingent payments, subject to milestone achievement and Molecule's election of cash or equity. Shuttle said the acquisition adds an AI molecular modeling and predictive analytics platform to its drug discovery and development capabilities.
Shuttle Pharmaceuticals (NASDAQ: SHPH) entered a securities purchase agreement with a single investor to raise approximately $2.5 million in gross proceeds via the sale of a pre-funded warrant that can be exercised into up to 625,156 shares at an effective price of $4.00 per share. The price is described as above-the-market under Nasdaq rules. The Offering is expected to close on or about November 4, 2025, subject to customary closing conditions.
WestPark Capital is the exclusive placement agent. The company intends to use net proceeds for marketing, general corporate purposes and working capital and has agreed to file registration statement(s) to cover resale of shares issuable upon exercise of the pre-funded warrant.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd. ("Molecule"), a Canadian AI molecular discovery company, for a $10 million total purchase price payable in cash and Shuttle common stock.
The final cash/equity mix will be determined by Shuttle and payments are subject to performance milestones. Closing requires mutual due diligence and execution of definitive agreements with customary conditions.
The company said the acquisition aims to expand Shuttle's AI molecular modeling and predictive analytics capabilities to support its precision radiotherapy drug-discovery pipeline.
Shuttle Pharmaceuticals (Nasdaq: SHPH) executed a non-binding letter of intent to acquire Molecule.ai, an AI drug-discovery platform founded by Dr. ZT Zhang, on October 10, 2025. The LOI contemplates Shuttle acquiring all rights to Molecule.ai and assuming its liabilities, with Molecule.ai extending its platform to support Drug-Target Interaction modeling and delivering a first version of an Agentic AI mode.
Consideration is a $10 million purchase price payable at closing in a mix of cash and Shuttle common shares and subject to milestone completion; specific milestone terms are to be determined by both parties.
Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.
Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.
Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving radiation therapy outcomes, provided a Q2 2025 corporate update highlighting significant progress in its clinical trials. The company's Phase 2 trial of Ropidoxuridine for glioblastoma treatment has reached 63% enrollment, with 72% of enrolled patients completing all seven cycles and reporting good tolerability.
Key financial developments include securing $4.25 million through a private placement, ending Q2 with $4.8 million in cash. The company completed a reverse stock split for Nasdaq compliance and strengthened its leadership by appointing George Scorsis as Board Chairman and Christopher Cooper to the Board. The Phase 2 trial completion is expected in late 2025, with data readouts anticipated in 2026.
Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving cancer radiation therapy outcomes, has completed a $4.25 million private placement with an accredited investor. The company issued 1,180,877 shares of common stock (or pre-funded warrants) at $3.60 per share, priced at-the-market under Nasdaq rules.
The net proceeds will be used for potential acquisitions, marketing, and general corporate purposes. WestPark Capital served as the exclusive placement agent. The company has agreed to file registration statements with the SEC for the resale of the shares and warrant shares.